Glenmark Life Sciences IPO Details
Glenmark Life Sciences IPO description – Glenmark Life Sciences – a wholly-owned subsidiary of Glenmark Pharmaceuticals – is a developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Its API portfolio comprises specialized and profitable products, including niche and technically complex molecules. The company is also increasingly providing contract development and manufacturing operations (CDMO) services to multinational and specialty pharmaceutical companies.
Its parent and promoter, Glenmark Pharmaceuticals is a global pharmaceutical company with a long operating history having been established in 1977. In 2001-2002, Glenmark launched the API manufacturing business by setting up a manufacturing facility in Kurkumbh in the state of Maharashtra. In 2019, the API manufacturing business of Glenmark was sold and spun off into Glenmark Life Sciences.
The company’s products are sold in both regulated markets and emerging markets. For the nine months ended 31 December 2020, its revenue from regulated market products accounted for 60.1% of its total revenues from operations. The company works with 16 of the 20 largest generic companies globally. As of 31 December 2020, it had a portfolio of 120 molecules globally and sold its APIs in India and exported its APIs to multiple countries in Europe, North America, Latin America, Japan and the rest of the world (ROW). As of 7 April 2021, it had filed 399 Drug Master Files (DMFs) and Certificates of suitability to the monographs of the European Pharmacopoeia (CEPs) across various major markets (i.e. United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia).
Promoters of Glenmark Life Sciences – Glenmark Pharmaceuticals Limited
| Glenmark Life Sciences IPO details | |
| Subscription Dates | 27 – 29 July 2021 |
| Price Band | INR695 – 720 per share |
| Fresh issue | INR1,060 crore |
| Offer For Sale | 63,00,000 shares (INR437.85 – 453.60 crore) |
| Total IPO size | INR1,497.85 – 1,513.6 crore |
| Minimum bid (lot size) | 20 shares |
| Face Value | INR2 per share |
| Retail Allocation | 35% |
| Listing On | NSE, BSE |
Glenmark Life Sciences Financial Performance (in INR crore)
| Â | FY2018 | FY2019 | FY2020 | FY2021 |
| Revenue | 1,202.2 | 1,405.5 | 1,549.3 | 1,886.0 |
| Expenses | 892.8 | 1,001.7 | 1,128.2 | 1,415.0 |
| Net income | 229.5 | 293.1 | 313.6 | 351.1 |
| Margin (%) | 19.1 | 20.9 | 20.2 | 18.6 |
More about Glenmark Life Sciences IPO
Registrar of Glenmark Life Sciences IPO
KFin Technologies Private Limited Selenium Tower B, Plot 31-32, Gachibowli, Nanakramguda, Hyderabad – 500 032, Telangana
Phone:Â +91 40 6716 2222Â
Fax:Â +91 40 2343 1551
Email:Â [email protected] Website:Â www.kfintech.com
Glenmark Life Sciences Contact Details
Glenmark Life Sciences Limited
Glenmark House,
B. D. Sawant Marg, Andheri (East),
Mumbai 400099, Maharashtra
Phone: +91 2189 234246
Email: [email protected]
Website:Â www.glenmarklifesciences.com
Valuation of Glenmark Life Sciences (as of FY2021)
Earnings Per Share (EPS): INR32.61
Price/Earnings (PE ratio): 21.31 – 22.08
Return on Net Worth (RONW): 46.71%
Net Asset Value (NAV): INR69.82 per share
Glenmark Life Sciences IPO GMP Daily Trend
| Date | Glenmark IPO GMP | Kostak | Subject to Sauda |
| 5 August 2021 | INR90 | – | – |
| 4 August 2021 | INR90 | – | INR2,000 |
| 3 August 2021 | INR100 | INR180 | INR2,000 |
| 2 August 2021 | INR110 | INR180 | INR2,000 |
| 31 July 2021 | INR130 | INR250 | INR2,300 |
| 30 July 2021 | INR150 | INR300 | INR2,500 |
| 29 July 2021 | INR150 | INR300 | INR2,500 |
| 28 July 2021 | INR150 | INR300 | INR2,500 |
| 27 July 2021 | INR170 | INR300 | INR2,500 |
| 26 July 2021 | INR220 | INR300 | INR2,800 |
| 23 July 2021 | INR250 | INR410 | INR3,800 |
| 22 July 2021 | INR250 | INR430 | INR4,200 |
| 21 July 2021 | INR280 | INR450 | INR4,700 |
Â
Glenmark Life Sciences IPO Subscription Details (no. of times, at 5 PM)
| Category | Shares Offered | Day 1 | Day 2 | Day 3 |
| QIB | 42,42,379 | 0.00 | 1.39 | 36.97 |
| NII | 32,32,770 | 0.85 | 3.40 | 122.54 |
| Retail | 75,43,130 | 5.17 | 9.28 | 14.63 |
| Total | 1,50,18,279 | 2.78 | 5.78 | 44.17 |
Glenmark Life Sciences IPO Reviews
Ajcon Global – Subscribe
Angel Broking – Subscribe
Anand Rathi – Subscribe
Arihant Capital – Subscribe
Ashika Research – Subscribe
BP Wealth – Subscribe
Choice Broking – Subscribe
Elite Wealth – Subscribe
Hem Securities – Subscribe
ICICIdirect – Subscribe
Marwadi Financial Services – Subscribe
Prabhudas Lilladher – Subscribe
Samco – Subscribe for listing gains
SMC Global – 3/5
Ventura Securities – Subscribe
Glenmark Life Sciences IPO Allotment Status
Glenmark Life Sciences IPO allotment is now available on KFin Technologies’ website. Click on this link to get allotment status.Â
Listing Performance of Glenmark Life Sciences
IPO Opening Date: 27 July 2021
IPO Closing Date: 29 July 2021
Finalisation of Basis of Allotment: 3 August 2021
Initiation of refunds: 4 August 2021
Transfer of shares to demat accounts: 5 August 2021
Listing Date: 6 August 2021
Opening Price on NSE: INR750 per share (up 4.17% from IPO price)
Closing Price on NSE: INR746 per share (up 3.61% from IPO price)
This looks like a good investment option but price is not known. Financially it is doing great and API/CDMO has bright future according to Sajal Kapoor. I will buy on listing if I don’t get allotment.
Is there share holder quota in glenmark life ipo or not ?
No shareholder quota! Thisis not fair I purchased glenmark shares for this ipo
is there is any preference to glenmark share holders
The IPO of API manufacturer Glenmark Life Sciences is scheduled to hit the markets on July 27th, marking this year’s 29th public offering.
The company was spun off as a wholly-owned API business subsidiary of Glenmark Pharmaceuticals in 2018.
Even though it has been doing some good business owing to rising market and policy winds favouring generics and patent liberation, this IPO may not have come at a particularly good time, in light of Glenmark Life’s financial obligation to its parent.